<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X11427958</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X11427958</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Endogenous Patient Responses and the Consistency Principle in Cost-Effectiveness Analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liu</surname><given-names>Liqun</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Rettenmaier</surname><given-names>Andrew J.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Saving</surname><given-names>Thomas R.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<aff id="aff1-0272989X11427958">Texas A&amp;M University, College Station, TX (LL, AJR, TRS)</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0272989X11427958">Liqun Liu, PhD, Private Enterprise Research Center, Texas A&amp;M University, College Station, TX 77843-4231; telephone: (979) 845-7723; fax: (979) 845-6636; e-mail: <email>lliu@tamu.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>488</fpage>
<lpage>497</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>11</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>9</month>
<year>2011</year>
</date>
</history>
<abstract>
<p>In addition to incurring direct treatment costs and generating direct health benefits that improve longevity and/or health-related quality of life, medical interventions often have further or “unrelated” financial and health impacts, raising the issue of what costs and effects should be included in calculating the cost-effectiveness ratio of an intervention. The “consistency principle” in medical cost-effectiveness analysis (CEA) requires that one include both the cost and the utility benefit of a change (in medical expenditures, consumption, or leisure) caused by an intervention or neither of them. By distinguishing between exogenous changes directly brought about by an intervention and endogenous patient responses to the exogenous changes, and within a lifetime utility maximization framework, this article addresses 2 questions related to the consistency principle: 1) how to choose among alternative internally consistent exclusion/inclusion rules, and 2) what to do with survival consumption costs and earnings. It finds that, for an endogenous change, excluding or including both the cost and the utility benefit of the change does not alter cost-effectiveness results. Further, in agreement with the consistency principle, welfare maximization implies that consumption costs and earnings during the extended life directly caused by an intervention should be included in CEA.</p>
</abstract>
<kwd-group>
<kwd>consistency principle</kwd>
<kwd>cost-effectiveness analysis</kwd>
<kwd>quality-adjustified life-years</kwd>
<kwd>survival consumption costs</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May–June 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In addition to incurring direct treatment costs and generating direct health benefits that improve longevity and/or health-related quality of life, medical interventions often have further or “unrelated” financial and health impacts. For example, any life-extending intervention would cause increased future consumption costs and/or increased future labor earnings—referred to in the literature on medical cost-effectiveness analysis (CEA) as survival consumption costs and survival earnings, respectively—simply because of the resulting longer life. On the other hand, a new, effective procedure for a particular form of cancer may, by extending life, encourage some patients to undertake other medical interventions, therefore incurring costs and generating benefits associated with the interventions induced by the cancer procedure.</p>
<p>These “unrelated” financial and health impacts derived from a medical intervention, as opposed to the direct treatment costs and the direct health effects of the intervention, have been considered as imposing a challenge to medical CEA. Specifically, a question frequently asked in the medical CEA literature is the following: in calculating the cost-effectiveness ratio for an intervention, which of its unrelated financial and health impacts should be explicitly accounted for?</p>
<p>Health economists have proposed different answers to this question, and the controversy is particularly noticeable regarding the exclusion/inclusion of survival consumption costs and survival earnings.<sup><xref ref-type="bibr" rid="bibr1-0272989X11427958">1</xref><xref ref-type="bibr" rid="bibr2-0272989X11427958"/><xref ref-type="bibr" rid="bibr3-0272989X11427958"/><xref ref-type="bibr" rid="bibr4-0272989X11427958"/><xref ref-type="bibr" rid="bibr5-0272989X11427958"/><xref ref-type="bibr" rid="bibr6-0272989X11427958"/>–<xref ref-type="bibr" rid="bibr7-0272989X11427958">7</xref></sup> Two studies stand out in their unique, but very different, methodologies and in their divergent conclusions. Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> used a very general lifetime utility maximization model to address a host of issues in medical CEA. The best-known conclusion from Meltzer’s analysis<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> is that welfare maximization requires that survival consumption costs and survival earnings during the extended life directly caused by an intervention be included in the intervention’s CEA.</p>
<p>On the other hand, Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> proposed to use logical consistency as the organizing principle in the determination of which costs and health effects of an intervention should or should not be included in its cost-effectiveness ratio. In a nutshell, the consistency principle of Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> states that, in the evaluation of a medical intervention, one should either include both the cost and the utility benefit of a change caused by the intervention or include neither of them. As Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> explained, this simple principle is very powerful in giving guidance regarding exclusion/inclusion of many items in CEA such as travel and time costs, informal care, unrelated medical care costs, and so on. Most recommendations of Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> based on the consistency principle are noncontroversial. However, in contrast to Meltzer,<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> argued that survival consumption costs and earnings should be excluded because quality-adjusted life years (QALYs) are constructed using a methodology that generally recognizes only the utility from health. Including survival consumption costs and earnings without accounting for the utility gain from the survival consumption and the utility loss from survival labor supply would, according to Nyman,<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> violate the consistency principle.</p>
<p>The first motivation behind the present article is to address the issue of whether survival consumption costs and earnings due to an intervention should be included in the numerator of the cost-effectiveness ratio when only the QALY gain from the intervention is included in the denominator. In the tradition of Pliskin and others,<sup><xref ref-type="bibr" rid="bibr10-0272989X11427958">10</xref></sup> Bleichrodt and others,<sup><xref ref-type="bibr" rid="bibr11-0272989X11427958">11</xref></sup> and especially Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> to use the QALY measure for health outcomes, we construct a lifetime utility maximization framework that is consistent with health outcomes being measured in QALYs. Our framework generalizes the previous QALY-consistent frameworks by including leisure, in addition to longevity, health-related quality of life, and consumption. Although our framework is more restrictive than Meltzer’s,<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> it has the advantage that the health improvements from an intervention are measured by a gain in the QALY measure. Importantly, we obtain the same result as Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup>: welfare maximization requires that survival consumption costs and earnings during the extended life directly caused by an intervention be included in CEA. Then, we go further to explain that this result does not violate the consistency principle. To the contrary, excluding survival consumption costs and earnings within our framework would violate the consistency principle.</p>
<p>There is a second overlapping area between Meltzer’s<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> and Nyman’s<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> analyses that has been insufficiently explored, which provides the second motivation behind the present article. Nyman<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> raised a further question about the consistency principle, namely how to choose among alternative internally consistent exclusion/inclusion rules regarding the costs and utility benefits of an intervention. We find that an often-neglected result in Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> is highly relevant for Nyman’s<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> inquiry. Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> distinguished between 2 kinds of survival consumption costs and earnings: those that result from changes in survival directly caused by an intervention under evaluation, and those that result from changes in survival due to (optimal) marginal adjustments in other medical interventions. Suppose, for example, a cancer screening test extends the life of a cancer patient with diabetes by reducing the mortality from the cancer. The new, improved prospect on life may in turn encourage the patient to be more aggressive with his diabetes treatment and therefore extend life further. Survival consumption costs and earnings will be incurred during both types of longevity extensions. While Meltzer’s<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> position on the former type of survival consumption costs and earnings is now well known, his position on the latter type of survival consumption costs and earnings is also interesting. Specifically, Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> pointed out that the survival consumption costs and earnings due to marginal adjustments in other medical interventions (the more aggressive diabetes treatment in the above example) should not be included unless the health benefits from those adjustments are also included. In addition, he noted that as long as consistency is maintained, the inclusion of future costs (and associated health benefits) that result from an individual’s adjustments to an intervention does not affect the evaluation outcome based on the envelope theorem.<sup><xref ref-type="fn" rid="fn1-0272989X11427958">a</xref></sup></p>
<p>Given Nyman’s<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> inquiry and Meltzer’s<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> underexplored envelope theorem result, the present article more explicitly distinguishes between 2 types of changes caused by an intervention: those exogenous changes directly brought about by an intervention, and those endogenous changes resulting from the patient’s optimal responses to the exogenous changes. We find that for an endogenous change, excluding or including both the cost and the utility benefit of the change makes no difference to the evaluation outcome.</p>
<p>Much of the “unrelated” financial and health impacts ultimately attributable to an intervention under evaluation arise because the intervention would induce a patient to make further choices in health care, consumption, and labor supply. Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> characterized unrelated medical care as “care to treat another disease that is necessitated by the effectiveness of treatment A in treating the disease in question and keeping the patient alive”.<sup>(p422)</sup> Obviously, whether and how aggressively to undertake the unrelated medical care is a matter of individual choice. Regarding unrelated survival consumption costs and survival earnings, as pointed out earlier, Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> distinguished between 2 kinds of survival consumption costs and earnings: those from the extended life directly caused by an intervention under evaluation, and those from the extended life due to the patient’s optimal adjustments in other medical interventions. An intervention may also generate unrelated changes in consumption and labor supply without extending longevity. For example, an effective arthritis treatment, in addition to relieving pain, would also enable the patient to work and consume more. Again, it remains the patient’s decision as to how much more to work and consume.</p>
<p>The article is organized as follows. In the next section, we construct a QALY-consistent lifetime utility specification that incorporates preferences not only on longevity and health-related quality of life but also on consumption and leisure, so that the health outcome of an intervention can be unambiguously measured with a gain in the QALY measure. Next, we introduce 2 kinds of health care expenditures: an exogenous expenditure that is subject to CEA, and an endogenous expenditure that the individual chooses on his own. Given the exogenous health expenditure, the individual chooses the endogenous health expenditure and the consumption and leisure levels that maximize his utility. After that, we derive the cost-effectiveness criterion that is implied by welfare maximization and relate it to the 2 questions about the consistency principle: 1) how to choose among alternative internally consistent exclusion/inclusion rules, and 2) what to do with the survival consumption costs and earnings based on the consistency principle. The conclusion is drawn in the last section.</p>
<sec id="section1-0272989X11427958">
<title>A QALY-Consistent Lifetime Utility Specification with Consumption and Leisure</title>
<p>Health outcomes of medical interventions generally include extended longevity and/or improved health-related quality of life. A widely used measure of health outcomes that combines both longevity and health-related quality of life is QALYs.<sup><xref ref-type="bibr" rid="bibr14-0272989X11427958">14</xref></sup> The QALY measure assigns a weight (<italic>q<sub>i</sub></italic>)to each period of life (<italic>T<sub>i</sub></italic>) that has a constant health-related quality of life, with</p>
<p>
<disp-formula id="disp-formula1-0272989X11427958">
<mml:math display="block" id="math1-0272989X11427958">
<mml:mrow>
<mml:mi>QALYs</mml:mi>
<mml:mo>=</mml:mo>
<mml:mo>∑</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq1.tif"/>
</disp-formula>
</p>
<p>It is well known that some restrictive assumptions have to be imposed on individual preferences for the QALY measure to be consistent with individual preferences. For example, in the special case of chronic (constant) health-related quality of life, Pliskin and others<sup><xref ref-type="bibr" rid="bibr10-0272989X11427958">10</xref></sup> proved that the QALY measure</p>
<p>
<disp-formula id="disp-formula2-0272989X11427958">
<mml:math display="block" id="math2-0272989X11427958">
<mml:mrow>
<mml:mi>QALYs</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>qT</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq2.tif"/>
</disp-formula>
</p>
<p>where <italic>q</italic> is the constant health status and <italic>T</italic> = ∑<italic>T<sub>i</sub></italic> is the length of life, represents individual preferences over longevity and health-related quality of life under the conditions of “utility independence”, “constant proportional tradeoffs of longevity for health status”, and “risk neutrality for life years”. Bleichrodt and others<sup><xref ref-type="bibr" rid="bibr11-0272989X11427958">11</xref></sup> later relaxed those conditions to a mere “risk neutrality” condition along with a “zero condition” that, for a duration of zero life years, all quality of life levels are equivalent.</p>
<p>However, health, which consists of both longevity and health-related quality of life, is not the only aspect that matters for individual welfare. To investigate the issue of medical resource allocation, in terms of QALYs, in the broader context of overall welfare maximization, Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> extended the individual preferences to cover not only longevity and health-related quality of life but also consumption. In this extended framework of individual preferences where consumption also comes into play, they showed that the QALY measure emerges as the true representation of individual preferences over health outcomes under the following 3 conditions: 1) the lifetime utility function is additive over time, 2) the instantaneous utility function is multiplicative in the utility of consumption and the utility of health status, and 3) the utility of consumption is constant over time.</p>
<p>Still, the framework of Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> does not include preferences over leisure, which makes their framework inadequate for addressing some issues in CEA of which time is an element, including time costs and labor earnings. In the following, we construct a QALY-consistent lifetime utility maximization framework that includes not only longevity, health-related quality of life, and consumption but also leisure. The framework is QALY consistent in the sense that the individual preferences over longevity and health-related quality of life are captured by the QALY measure.</p>
<p>The lifetime utility maximization framework adopted in this article is a generalization of those in Dow and others,<sup><xref ref-type="bibr" rid="bibr15-0272989X11427958">15</xref></sup> Bleichrodt and Quiggin,<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> and Liu and others.<sup><xref ref-type="bibr" rid="bibr16-0272989X11427958">16</xref></sup> A representative individual chooses consumption and leisure over time, <italic>c(t)</italic> and <italic>l(t)</italic>, to maximize the lifetime utility</p>
<p>
<disp-formula id="disp-formula3-0272989X11427958">
<mml:math display="block" id="math3-0272989X11427958">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>qu</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq3.tif"/>
</disp-formula>
</p>
<p>where <italic>T</italic> is the length of life,<sup><xref ref-type="fn" rid="fn2-0272989X11427958">b</xref></sup><italic>q</italic> is the (constant) health-related quality of life, and <italic>u(c,l)</italic> is a strictly increasing and strictly concave function of <italic>c</italic> and <italic>l</italic>.<sup><xref ref-type="fn" rid="fn3-0272989X11427958">c</xref></sup> The lifetime budget constraint is</p>
<p>
<disp-formula id="disp-formula4-0272989X11427958">
<mml:math display="block" id="math4-0272989X11427958">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>dt</mml:mi>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>M</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq4.tif"/>
</disp-formula>
</p>
<p>where <italic>w</italic> is the wage rate, <inline-formula id="inline-formula1-0272989X11427958"><mml:math display="inline" id="math5-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the total time available for leisure and labor at any given point of time, <italic>W</italic><sub>0</sub> is the individual’s initial wealth, and <italic>M</italic> is the total lifetime spending on medical care.</p>
<p>Following Dow and others,<sup><xref ref-type="bibr" rid="bibr15-0272989X11427958">15</xref></sup> Bleichrodt and Quiggin,<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> and Liu and others,<sup><xref ref-type="bibr" rid="bibr16-0272989X11427958">16</xref></sup> we assume no discounting in both the lifetime utility (<xref ref-type="disp-formula" rid="disp-formula3-0272989X11427958">equation 3</xref>) and the lifetime budget constraint (<xref ref-type="disp-formula" rid="disp-formula4-0272989X11427958">equation 4</xref>). This no-discounting assumption implies perfect smoothing of consumption so that condition 3 in Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> is satisfied.<sup><xref ref-type="fn" rid="fn4-0272989X11427958">d</xref></sup> In addition, we assume that <italic>w</italic> and <inline-formula id="inline-formula2-0272989X11427958"><mml:math display="inline" id="math6-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> are constant over time. In the <xref ref-type="app" rid="app1-0272989X11427958">Appendix</xref>, we show that this additional assumption, along with the no-discounting assumption, implies perfect smoothing of leisure as well.</p>
<p>As the result of optimal consumption and leisure smoothing under these assumptions, the lifetime utility becomes</p>
<p>
<disp-formula id="disp-formula5-0272989X11427958">
<mml:math display="block" id="math7-0272989X11427958">
<mml:mrow>
<mml:mi>Tqu</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq5.tif"/>
</disp-formula>
</p>
<p>and the lifetime budget constraint becomes</p>
<p>
<disp-formula id="disp-formula6-0272989X11427958">
<mml:math display="block" id="math8-0272989X11427958">
<mml:mrow>
<mml:mi>Tc</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>Tw</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>M</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq6.tif"/>
</disp-formula>
</p>
<p>The assumption that <italic>w</italic> and <inline-formula id="inline-formula3-0272989X11427958"><mml:math display="inline" id="math9-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> are constant over time is, of course, quite restrictive. However, like the assumption of no discounting, it is necessary for the lifetime utility maximization framework to be consistent with the QALY measure. Moreover, it is not terribly unreasonable to assume that <italic>w</italic> and <inline-formula id="inline-formula4-0272989X11427958"><mml:math display="inline" id="math10-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> are constant over time if one can assume that the health status <italic>q</italic> is constant over time, which is a standard assumption made in various theoretical studies that provide the welfare foundation for using the QALY to measure health outcomes.<sup><xref ref-type="fn" rid="fn5-0272989X11427958">e</xref></sup></p>
<p>Note that although the lifetime utility specification of <xref ref-type="disp-formula" rid="disp-formula5-0272989X11427958">equation 5</xref> is based on some strong assumptions needed for individual preferences to be consistent with the QALY measure, it is nonetheless in line with the state-dependent utility specification often seen in the health economics literature. In particular, the multiplicative form in <xref ref-type="disp-formula" rid="disp-formula5-0272989X11427958">equation 5</xref> implies that higher <italic>q</italic> would increase the marginal utility from consumption or leisure, which is consistent with the empirical evidence that health and consumption are generally complementary with each other.<sup><xref ref-type="fn" rid="fn6-0272989X11427958">f</xref></sup></p>
</sec>
<sec id="section2-0272989X11427958">
<title>Exogenous Health Interventions and Endogenous Patient Responses</title>
<p>The health production has 2 inputs: an exogenous health care expenditure <italic>H</italic> that pays for all interventions that are subject to CEA, and an endogenous health care expenditure <italic>X</italic> that the individual optimally chooses to maximize utility given the level of the exogenous health care expenditure. The division between the 2 kinds of health care expenditures is an important feature of our model and is intended to capture the fact that, while CEAs tend to focus on interventions aimed at specific diseases (e.g., heart diseases, digestive disorders, or cancers), individuals also have other health problems about which decisions must be made.<sup><xref ref-type="fn" rid="fn7-0272989X11427958">g</xref></sup> As the result of these 2 types of health expenditures, the longevity and health-related quality of life in <xref ref-type="disp-formula" rid="disp-formula5-0272989X11427958">equations 5</xref> and <xref ref-type="disp-formula" rid="disp-formula6-0272989X11427958">6</xref> can be generally written as <italic>T</italic>(<italic>H, X</italic>) and <italic>q</italic>(<italic>H, X</italic>), respectively.<sup><xref ref-type="fn" rid="fn8-0272989X11427958">h</xref></sup></p>
<p>Therefore, for any given level of the exogenous health care expenditure <italic>H</italic> (representing the health interventions that are subject to CEA), the representative individual’s problem is to choose the endogenous health expenditure <italic>X</italic>, consumption <italic>c</italic>, and leisure <italic>l</italic> to maximize the lifetime utility</p>
<p>
<disp-formula id="disp-formula7-0272989X11427958">
<mml:math display="block" id="math11-0272989X11427958">
<mml:mrow>
<mml:mi>Q</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq7.tif"/>
</disp-formula>
</p>
<p>subject to the lifetime budget constraint</p>
<p>
<disp-formula id="disp-formula8-0272989X11427958">
<mml:math display="block" id="math12-0272989X11427958">
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq8.tif"/>
</disp-formula>
</p>
<p>where <italic>Q</italic>(<italic>H, X</italic>) ≡<italic>T</italic>(<italic>H, X</italic>)<italic>q</italic>(<italic>H, X</italic>) is the QALY-measured health outcome under health care inputs <italic>H</italic> and <italic>X</italic>.</p>
<p>The Lagrange function of the utility maximization problem is</p>
<p>
<disp-formula id="disp-formula9-0272989X11427958">
<mml:math display="block" id="math13-0272989X11427958">
<mml:mrow>
<mml:mi>Γ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo>;</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>≡</mml:mo>
<mml:mi>Q</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>}</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq9.tif"/>
</disp-formula>
</p>
<p>and the first-order conditions are</p>
<p>
<disp-formula id="disp-formula10-0272989X11427958">
<mml:math display="block" id="math14-0272989X11427958">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq10.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula11-0272989X11427958">
<mml:math display="block" id="math15-0272989X11427958">
<mml:mrow>
<mml:mi>Q</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>c</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mi>T</mml:mi>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mtext>and</mml:mtext>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula11-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq11.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula12-0272989X11427958">
<mml:math display="block" id="math16-0272989X11427958">
<mml:mrow>
<mml:mi>Q</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mi>Tw</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula12-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq12.tif"/>
</disp-formula>
</p>
<p>where λ is the marginal utility of wealth. The utility maximization problem yields demands for endogenous health care expenditure, instantaneous consumption, and leisure, for any given exogenous health care expenditure <italic>H: X</italic>(<italic>H</italic>), <italic>c</italic>(<italic>H</italic>), and <italic>l</italic>(<italic>H</italic>). The value function (the maximized lifetime utility under any <italic>H</italic>) is</p>
<p>
<disp-formula id="disp-formula13-0272989X11427958">
<mml:math display="block" id="math17-0272989X11427958">
<mml:mrow>
<mml:mi>V</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>≡</mml:mo>
<mml:mi>Q</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>u</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula13-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq13.tif"/>
</disp-formula>
</p>
</sec>
<sec id="section3-0272989X11427958">
<title>The Cost-Effectiveness Criterion and the Consistency Principle</title>
<p>Now consider a new health intervention represented by a marginal increase in the exogenous health expenditure <italic>H</italic>. The intervention improves individual welfare if and only if <inline-formula id="inline-formula5-0272989X11427958"><mml:math display="inline" id="math18-0272989X11427958"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>dV</mml:mi></mml:mrow><mml:mrow><mml:mi>dH</mml:mi></mml:mrow></mml:mfrac><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>. From <xref ref-type="disp-formula" rid="disp-formula9-0272989X11427958">equation 9</xref> and the envelope theorem,</p>
<p>
<disp-formula id="disp-formula14-0272989X11427958">
<mml:math display="block" id="math19-0272989X11427958">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>dV</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>dH</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula14-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq14.tif"/>
</disp-formula>
</p>
<p>Note that <xref ref-type="disp-formula" rid="disp-formula14-0272989X11427958">equation 14</xref> can also be directly derived from <xref ref-type="disp-formula" rid="disp-formula13-0272989X11427958">equation 13</xref> using the first-order conditions (<xref ref-type="disp-formula" rid="disp-formula10-0272989X11427958">equations 10</xref>–<xref ref-type="disp-formula" rid="disp-formula12-0272989X11427958">12</xref>) and the budget constraint (<xref ref-type="disp-formula" rid="disp-formula8-0272989X11427958">equation 8</xref>) (<xref ref-type="app" rid="app1-0272989X11427958">Appendix</xref>).</p>
<p>Therefore, the marginal increase in the exogenous health expenditure improves welfare if and only if</p>
<p>
<disp-formula id="disp-formula15-0272989X11427958">
<mml:math display="block" id="math20-0272989X11427958">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>&lt;</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula15-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq15.tif"/>
</disp-formula>
</p>
<p>The cost-effectiveness criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>) is a decision rule grounded in welfare economics. Its left-hand side (LHS) is the cost-effectiveness ratio of an intervention under evaluation, with the numerator and the denominator being costs and QALY-measured effectiveness of the intervention, respectively. Its right-hand side (RHS) is the critical value of the cost-effectiveness ratio.<sup><xref ref-type="fn" rid="fn9-0272989X11427958">i</xref></sup> As this criterion indicates, welfare maximization requires that we adopt the intervention if and only if its cost-effectiveness ratio is less than the critical value. When 2 mutually exclusive interventions are evaluated, the incremental cost-effectiveness ratio of one intervention relative to its alternative—the difference in their costs divided by the difference in their QALY-measured effectiveness—is calculated, and the former intervention is chosen if and only if the incremental cost-effectiveness ratio is less than the critical value.</p>
<p>According to the cost-effectiveness criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>), the “effectiveness” of an intervention, showing up in the denominator of the LHS of <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>, includes only its direct health effects, measured by a gain in the QALY measure,<italic>Q<sub>H</sub></italic>. More interestingly, the “costs” of an intervention that should be explicitly included in CEA, as indicated in the numerator of the LHS of <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>, include the direct treatment cost itself (the $1 marginal increase in <italic>H</italic>), the survival consumption cost <italic>T<sub>H</sub>c</italic> for the consumption during the increased longevity caused by the intervention at the original consumption level <italic>c</italic>, and the survival earnings (as a negative cost) <italic>T<sub>H</sub>w</italic>(<inline-formula id="inline-formula6-0272989X11427958"><mml:math display="inline" id="math21-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>) during the increased longevity holding leisure at its original level <italic>l</italic>.</p>
<p>The criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>) has 2 noticeable features. First, all costs and effects from endogenous patient responses to an intervention—namely costs and effects associated with changes in the endogenous health care expenditure <italic>X</italic>, annual consumption <italic>c</italic>, and leisure <italic>l</italic>—are absent in the cost-effectiveness ratio of <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>. Second, as the numerator of the cost-effectiveness ratio indicates, survival consumption costs and survival earnings, <italic>T<sub>H</sub>c</italic> and <italic>T<sub>H</sub>w</italic>(<inline-formula id="inline-formula7-0272989X11427958"><mml:math display="inline" id="math22-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>), should be recognized as costs (or negative costs for the earnings) on par with the $1 direct treatment costs of the intervention. These results are essentially the same as the ones derived in Meltzer.<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> However, our focus here is the consistency principle in medical CEA, and as we explain below, these 2 features are consistent with Nyman’s<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> consistency principle.</p>
<p>As articulated in Nyman,<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> consistency requires that one should either include both the cost and the utility benefit of a change caused by an intervention or exclude both of them. The first feature of the criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>) is consistent with that principle, at least when the “change” in question is a change in an endogenous choice variable caused by an intervention, because all costs and effects from changes in endogenous choice variables <italic>X, c</italic>, and <italic>l</italic> are absent in the cost-effectiveness ratio of <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>. Nyman<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> further raised an interesting question as to how to choose among alternative consistent inclusion/exclusion rules. Our answer to this question is that, at least for the cost and the utility benefit of a change in an endogenous variable, excluding or including both the cost and the utility benefit results in the same evaluation outcome, but it minimizes the informational requirements to exclude both the cost and the utility benefit. In other words, the criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>) is the cost-effectiveness rule that requires the least information to implement because it excludes all the costs and utility benefits associated with endogenous patient responses to an intervention.<sup><xref ref-type="fn" rid="fn10-0272989X11427958">j</xref></sup> To see why adding costs and utility benefits to <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref> in a consistent way would not alter the evaluation outcome, note that the cost of an endogenous change is exactly offset, in terms of welfare, by the utility benefit due to the same change. For example, when the endogenous health care expenditure <italic>X</italic> increases by a dollar in response to an intervention, the net cost is [1+<italic>T<sub>X</sub>c</italic>−<italic>T<sub>X</sub>w</italic>(<inline-formula id="inline-formula8-0272989X11427958"><mml:math display="inline" id="math23-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>)], where <italic>T<sub>X</sub>c</italic> is the consumption cost associated with the increased longevity caused by the $1 increase in <italic>X</italic> and <italic>T<sub>X</sub>w</italic>(<inline-formula id="inline-formula9-0272989X11427958"><mml:math display="inline" id="math24-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>) is the additional earnings from the increased longevity holding labor supply at its original level. This net financial cost translates into a utility cost of λ[<italic>1</italic>+<italic>T<sub>X</sub>c</italic>−<italic>T<sub>X</sub>w</italic>(<inline-formula id="inline-formula10-0272989X11427958"><mml:math display="inline" id="math25-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>)], where λ is the marginal utility of wealth. On the other hand, the utility benefit from the $1 increase in <italic>X</italic> is <italic>Q<sub>X</sub>u</italic>(<italic>c, l</italic>). According to the first-order condition (<xref ref-type="disp-formula" rid="disp-formula10-0272989X11427958">equation 10</xref>), the utility cost and the utility benefit are equal and cancel each other out with a zero net welfare effect. Similarly, the utility cost of a $1 endogenous increase in the annual consumption level <italic>c</italic> (or a one-unit endogenous increase in leisure <italic>l</italic>) is λ<italic>T</italic> (or λ<italic>T</italic><italic>w</italic>), which is completely neutralized by the utility benefit of such an increase, <italic>Qu<sub>c</sub></italic> (or <italic>Qu<sub>l</sub></italic>), as indicated by the first-order condition (<xref ref-type="disp-formula" rid="disp-formula11-0272989X11427958">equation 11</xref>) (or the first-order condition [<xref ref-type="disp-formula" rid="disp-formula12-0272989X11427958">equation 12</xref>]).</p>
<p>The equivalence of the 2 consistent treatments of the cost and the utility benefit of an endogenous response to an intervention, namely excluding or including both the cost and the utility benefit, was established in Meltzer.<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> One particularly interesting finding in Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> is that the additional consumption costs resulting from changes in survival due to optimal marginal adjustments in other medical interventions do not need to be included unless their utility benefits are also included.<sup><xref ref-type="fn" rid="fn11-0272989X11427958">k</xref></sup> The present article’s explicit discussion of the first-order conditions’ implications for choosing among alternative, consistent inclusion/exclusion rules regarding the costs and utility benefits of an endogenous patient response to an intervention provides an answer to the question raised in Nyman<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> about the scope of medical CEA.</p>
<p>While we generally recommend excluding both the costs and utility benefits associated with patient endogenous responses to an intervention to avoid unnecessary information collection, the exclusion method cannot be applied to changes directly caused by the intervention that are not part of patient responses. Excluding both the cost and utility benefit associated with an endogenous patient response itself may not be a valid option in practice because the measured QALY gain from an intervention may have already included the secondary health effects from an endogenous patient response to the intervention, and it may be impossible to separate the direct health effects from the intervention and the secondary health effects through optimal patient responses to the intervention. Moreover, there exist situations in which the exclusion option may fail to account for all the relevant (social) costs and benefits associated with the endogenous patient responses. One such situation is present when individual health care costs are subsidized by the government. That part of the health care costs borne by the government should always be included in the evaluation of an intervention because individuals do not take those costs or revenues into consideration when making their optimal choices.<sup><xref ref-type="bibr" rid="bibr7-0272989X11427958">7</xref></sup> Another situation in which the cost and utility benefit of an endogenous change (in the consumption or leisure level or in the medical care) may not cancel each other out is present when the change in question is large in scale. Then, there is likely to be a consumer surplus, a rent or a net benefit from the medical care. This is because individual decisions are made privately on the market, and they would not occur unless the value of the gains exceeded the costs (or the earnings exceeded the value of the leisure foregone). So, leaving both the cost and the benefit of a large transaction out is not neutral but instead would reduce the net benefit associated with the intervention.<sup><xref ref-type="bibr" rid="bibr22-0272989X11427958">22</xref></sup></p>
<p>Now, we can consider the second feature of the criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>) that survival consumption costs and survival earnings are treated as costs (or negative costs for earnings) the same way as the direct treatment costs of an intervention. It can be shown that including survival consumption costs and earnings in the numerator of the cost-effectiveness ratio is in agreement with Nyman’s<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> consistency principle. Let us begin with Nyman’s<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> argument for excluding the survival consumption costs and earnings. Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> argued that because the quality weighting of the life years does not consider the quality of life derived from consumption and leisure,<sup><xref ref-type="fn" rid="fn12-0272989X11427958">l</xref></sup> costs of survival consumption and earnings from survival labor supply should not be included in the numerator of the cost-effectiveness ratio. Otherwise, according to Nyman,<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> one would violate the consistency principle by including the cost but not the utility of survival consumption or including the earnings but not the disutility from survival labor supply. However, the additional utility gain from survival consumption or additional utility loss from survival labor supply is already captured by the QALY gain, <italic>Q<sub>H</sub></italic>. To see this, recall that the individual’s utility is measured by <italic>Qu</italic>(<italic>c, l</italic>). Importantly, note that survival consumption simply maintains the preintervention consumption level <italic>c</italic> for the extended life. Therefore, the utility gain from survival consumption is captured by the QALY gain, <italic>Q<sub>H</sub></italic>. Similarly, survival labor supply does not change the preintervention leisure level <italic>l</italic> but simply sustains <italic>l</italic> for the extended life. Therefore, the utility loss from survival labor supply is also captured by <italic>Q<sub>H</sub></italic>.<sup><xref ref-type="fn" rid="fn13-0272989X11427958">m</xref></sup> As a result, even though the QALY gain from an intervention does not explicitly consider consumption-related or leisure-related quality of life, including survival consumption costs and earnings in the numerator of the cost-effectiveness ratio satisfies the consistency principle.</p>
<p>Alternatively, it can be shown that excluding survival consumption costs or survival earnings from the numerator of the cost-effectiveness ratio when the QALY gain in the denominator is partly achieved through extended longevity would violate the consistency principle. According to the consistency principle, all costs incurred to achieve the QALY gain in the denominator should be included in the numerator. But from the total utility specification <italic>Qu</italic>(<italic>c, l</italic>), the QALY gain in the denominator unambiguously represents a certain gain in lifetime utility only when <italic>c</italic> and <italic>l</italic>, and hence <italic>u</italic>(<italic>c, l</italic>), are kept the same. To keep <italic>c</italic> and <italic>l</italic> the same when the longevity is extended by an intervention, survival consumption costs must be incurred, and survival earnings must be made. Therefore, survival consumption costs, survival earnings as negative costs, as well as the direct costs of the intervention are all the costs incurred to generate the utility gain represented by the QALY gain in the denominator of the cost-effectiveness ratio, even though the QALY gain itself includes only gains in longevity and health-related quality of life.<sup><xref ref-type="fn" rid="fn14-0272989X11427958">n</xref></sup></p>
<p>To summarize, we have formally derived a cost-effectiveness criterion with a cost-effectiveness ratio in which all costs and utility benefits associated with endogenous patient responses to an intervention are absent, and consumption costs and earnings (as negative costs) during the additional years directly caused by the intervention appear in the numerator alongside the direct costs of the intervention. Regarding the 2 questions related to the consistency principle—1) how to choose among alternative internally consistent exclusion/inclusion rules, and 2) how to treat the survival consumption costs and earnings in a way that is compatible with the consistency principle—we have shown that as far as an endogenous change is concerned, including or excluding both its cost and utility benefit does not make any difference to the evaluation outcome. We also showed that including survival consumption costs and earnings directly caused by an intervention holds true to the consistency principle but that excluding them does not.</p>
</sec>
<sec id="section4-0272989X11427958" sec-type="conclusions">
<title>Conclusion</title>
<p>The most basic idea of the utility maximization framework is that CEA must include all costs and benefits of an intervention and count each only once so there is no double counting.<sup><xref ref-type="bibr" rid="bibr6-0272989X11427958">6</xref>,<xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> The more subtle point addressed by the consistency principle is that there may be secondary adjustments in other inputs at the margin that may be included or excluded under certain assumptions. These need to be treated consistently in either being included or excluded. In this light, the consistency principle is a necessary but not sufficient one for measuring cost-effectiveness and has a specific scope of application relating to marginal adjustments in response to a medical intervention that is subject to CEA.</p>
<p>Within a QALY-consistent lifetime utility maximization framework and by explicitly distinguishing between exogenous changes directly brought about by an intervention and endogenous patient responses to the exogenous changes, this article addresses 2 questions related to the consistency principle: 1) how to choose among alternative internally consistent exclusion/inclusion rules, and 2) what to do with the survival consumption costs and earnings based on the consistency principle.</p>
<p>With regard to the first question, we find that, for an endogenous change resulting from the patient’s optimal response to an intervention, excluding or including both the cost and the utility benefit of the change makes no difference to the evaluation of the intervention. While the exclusion option seems to have an informational advantage, it may be impossible to implement in practice because of the difficulty to separate the direct health effects of an intervention from the health effects resulting from the patient’s endogenous responses to the intervention. In those “nonseparable” cases, one must include all of the costs and utility benefits associated with endogenous patient responses to an intervention.<sup><xref ref-type="fn" rid="fn15-0272989X11427958">o</xref></sup> Further, there exist situations in which the exclusion option fails to account for all the relevant (social) costs and benefits associated with an endogenous change. For those situations, including both (social) costs and utility benefits of an endogenous change is warranted.</p>
<p>With regard to the second question, we find that, consistent with the consistency principle, welfare maximization implies that survival consumption costs and earnings directly associated with an intervention should be included in the numerator of the cost-effectiveness ratio, even though the denominator of the cost-effectiveness ratio only includes the direct QALY gain from the intervention. Excluding the survival consumption costs and earnings would violate the consistency principle.</p>
<p>What would be our recommendations regarding the 2 examples in the introduction? For any life-extending intervention, survival consumption costs and survival earnings during the extended life caused directly by the intervention should be included in the intervention’s evaluation. Excluding them would violate the consistency principle. On the other hand, a new procedure that treats a particular form of cancer, thereby increasing life expectancy, may encourage some elderly patients to undertake other medical interventions. These secondary effects produce costs and generate benefits associated with improved health-related quality of life. Although either including or excluding both the costs and the benefits associated with these secondary effects would yield the identical evaluation outcome, the choice between them should be determined by how the health effects of an intervention are empirically measured.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-0272989X11427958">
<title>Appendix</title>
<sec id="section5-0272989X11427958">
<title>Optimal Consumption and Leisure Smoothing</title>
<p>A representative individual chooses consumption and leisure over time, <italic>c(t)</italic> and <italic>l(t)</italic>, to maximize the lifetime utility</p>
<p>
<disp-formula id="disp-formula16-0272989X11427958">
<mml:math display="block" id="math26-0272989X11427958">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>qu</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula16-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq16.tif"/>
</disp-formula>
</p>
<p>subject to the lifetime budget constraint</p>
<p>
<disp-formula id="disp-formula17-0272989X11427958">
<mml:math display="block" id="math27-0272989X11427958">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>dt</mml:mi>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>M</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula17-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq17.tif"/>
</disp-formula>
</p>
<p>where <italic>q</italic> is the health-related quality of life, <italic>w</italic> is the wage rate, <inline-formula id="inline-formula11-0272989X11427958"><mml:math display="inline" id="math28-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the total time available for leisure and labor at any given point of time, <italic>W</italic><sub>0</sub> is the individual’s initial wealth, and <italic>M</italic> is the total lifetime spending on medical care. Two critical assumptions underlying this lifetime utility maximization framework are that there is no discounting in both the utility expression and the budget constraint and that <italic>q, w</italic>, and <inline-formula id="inline-formula12-0272989X11427958"><mml:math display="inline" id="math29-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> are all constant over time.</p>
<p>The Lagrange function of the optimization problem is</p>
<p>
<disp-formula id="disp-formula18-0272989X11427958">
<mml:math display="block" id="math30-0272989X11427958">
<mml:mrow>
<mml:mtable align="right" width="80%">
<mml:mtr>
<mml:mtd columnalign="right" columnspan="1">
<mml:mrow>
<mml:mi>Γ</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>≡</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>qu</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="right" columnspan="1">
<mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mo>+</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>w</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>dt</mml:mi>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>W</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>M</mml:mi>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mo>∫</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>dt</mml:mi>
<mml:mo>}</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula18-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq18.tif"/>
</disp-formula>
</p>
<p>The first-order conditions are</p>
<p>
<disp-formula id="disp-formula19-0272989X11427958">
<mml:math display="block" id="math31-0272989X11427958">
<mml:mrow>
<mml:mtable align="right" width="80%">
<mml:mtr>
<mml:mtd columnalign="right" columnspan="1">
<mml:mrow>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>q</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>c</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="right" columnspan="1">
<mml:mrow>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mi>q</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mi>w</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula19-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq19.tif"/>
</disp-formula>
</p>
<p>which imply that <italic>c</italic>(<italic>t</italic>) is the same for all <italic>t</italic> and <italic>l</italic>(<italic>t</italic>) is the same for all <italic>t</italic>.</p>
</sec>
<sec id="section6-0272989X11427958">
<title>Derivation of <xref ref-type="disp-formula" rid="disp-formula14-0272989X11427958">Equation 14</xref> Using the First-Order Conditions and the Budget Constraint</title>
<p>From <xref ref-type="disp-formula" rid="disp-formula13-0272989X11427958">equation 13</xref>,</p>
<p>
<disp-formula id="disp-formula20-0272989X11427958">
<mml:math display="block" id="math32-0272989X11427958">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>dV</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>dH</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>c</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>l</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>Q</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula20-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq20.tif"/>
</disp-formula>
</p>
<p>Using the first-order conditions (<xref ref-type="disp-formula" rid="disp-formula10-0272989X11427958">equations 10</xref>–<xref ref-type="disp-formula" rid="disp-formula12-0272989X11427958">12</xref>), we have</p>
<p>
<disp-formula id="disp-formula21-0272989X11427958">
<mml:math display="block" id="math33-0272989X11427958">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>dV</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>dH</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Q</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>u</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>Tc</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>Twl</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>}</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula21-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq21.tif"/>
</disp-formula>
</p>
<p>Differentiating the budget constraint (<xref ref-type="disp-formula" rid="disp-formula8-0272989X11427958">equation 8</xref>), taking <italic>X, c</italic>, and <italic>l</italic> as functions of <italic>H</italic> (optimal patient responses to a given <italic>H</italic>), we have</p>
<p>
<disp-formula id="disp-formula22-0272989X11427958">
<mml:math display="block" id="math34-0272989X11427958">
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>c</mml:mi>
<mml:mo>+</mml:mo>
<mml:mi>Tc</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>Twl</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula22-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq22.tif"/>
</disp-formula>
</p>
<p>or</p>
<p>
<disp-formula id="disp-formula23-0272989X11427958">
<mml:math display="block" id="math35-0272989X11427958">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>H</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>c</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>X</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mi>w</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mover>
<mml:mrow>
<mml:mi>L</mml:mi>
</mml:mrow>
<mml:mo>¯</mml:mo>
</mml:mover>
<mml:mo>−</mml:mo>
<mml:mi>l</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mi>X</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>Tc</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>Twl</mml:mi>
<mml:mo>′</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula23-0272989X11427958" xlink:href="10.1177_0272989X11427958-eq23.tif"/>
</disp-formula>
</p>
<p>Substituting <xref ref-type="disp-formula" rid="disp-formula23-0272989X11427958">equation A2</xref> into <xref ref-type="disp-formula" rid="disp-formula21-0272989X11427958">equation A1</xref>, we obtain <xref ref-type="disp-formula" rid="disp-formula14-0272989X11427958">equation 14</xref>.</p>
</sec>
</app>
</app-group>
<notes>
<fn-group>
<fn fn-type="other" id="fn1-0272989X11427958">
<label>a.</label>
<p>Nevertheless, Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> pointed out that it may be difficult to distinguish between the health effects directly due to an exogenous intervention that is under evaluation and the health effects due to the endogenous patient responses to the intervention. Then, excluding both health effects and costs associated with the endogenous patient responses may not be a valid option in practice. In such situations, both these health effects and costs associated with the endogenous patient responses need to be included in CEA.</p>
</fn>
<fn fn-type="other" id="fn2-0272989X11427958">
<label>b.</label>
<p>In this article, mortality enters the discussion through the length of life <italic>T</italic>, which can be changed through exogenous health interventions and endogenous patient responses (see the next section for details). Alternatively, mortality can be captured by a more general survival function, as in Meltzer.<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup></p>
</fn>
<fn fn-type="other" id="fn3-0272989X11427958">
<label>c.</label>
<p>We assume <italic>q</italic>≥ 0 and <italic>u</italic>(<italic>c, l</italic>) ≥ 0. The nonnegativity of <italic>q</italic> and <italic>u</italic>(<italic>c, l</italic>) is imposed to rule out a quality of life (either health-related or health-unrelated) worse than death. While there exist situations in which health status or consumption level is so low that the individual prefers death to life, these situations are not normally considered in medical CEA.</p>
</fn>
<fn fn-type="other" id="fn4-0272989X11427958">
<label>d.</label>
<p>As pointed out by Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> and Liu and others,<sup><xref ref-type="bibr" rid="bibr16-0272989X11427958">16</xref></sup> perfect consumption smoothing can be obtained as long as the market rate of interest equals the individual’s subjective discount rate (the time preference rate). For further discussion of the no-discounting assumption, see Liu and others.<sup><xref ref-type="bibr" rid="bibr16-0272989X11427958">16</xref></sup> Note also that conditions 1 and 2 in Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> are automatically satisfied from the lifetime utility specification (<xref ref-type="disp-formula" rid="disp-formula3-0272989X11427958">equation 3</xref>).</p>
</fn>
<fn fn-type="other" id="fn5-0272989X11427958">
<label>e.</label>
<p>Regarding the stringent conditions for QALY-based health outcome measures to be consistent with individual preferences, Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr17-0272989X11427958">17</xref></sup> pointed out that CEA that is based on the QALY measure is a better approximation of welfare-grounded cost-benefit analysis (CBA) when it is applied to working-age adults because they tend to have “relatively stable health status over the medium term, and if they are near the hump in the consumption profile, relatively stable consumption”.<sup>(p168)</sup></p>
</fn>
<fn fn-type="other" id="fn6-0272989X11427958">
<label>f.</label>
<p>For empirical evidence of such complementarities, see Viscusi and Evans<sup><xref ref-type="bibr" rid="bibr18-0272989X11427958">18</xref></sup> and Sloan and others.<sup><xref ref-type="bibr" rid="bibr19-0272989X11427958">19</xref></sup> In addition to Bleichrodt and Quiggin<sup><xref ref-type="bibr" rid="bibr12-0272989X11427958">12</xref></sup> and Liu and others,<sup><xref ref-type="bibr" rid="bibr16-0272989X11427958">16</xref></sup> Murphy and Topel<sup><xref ref-type="bibr" rid="bibr20-0272989X11427958">20</xref></sup> also adopted a utility specification in which health and utility from consumption and leisure are multiplicatively separable. On the other hand, there exist situations where health and consumption may be substitutes. For example, if an individual were disabled, the individual might appreciate consumption even more than when able bodied, especially when the consumption is service oriented.</p>
</fn>
<fn fn-type="other" id="fn7-0272989X11427958">
<label>g.</label>
<p>The division between the 2 types of health investment is context specific, that is, dependent on what specific health investment is subject to CEA. Given the context, however, such a division is relatively self-evident. A natural question here is why some health interventions are subject to cost-effectiveness evaluation but some other health interventions and most nonhealth products and services are not. The interventions involving CEA are often implicitly assumed to be financed by a third party, typically a government payer.</p>
</fn>
<fn fn-type="other" id="fn8-0272989X11427958">
<label>h.</label>
<p>We could have also allowed the wage rate (<italic>w</italic>) and the time available for leisure and work (<inline-formula id="inline-formula13-0272989X11427958"><mml:math display="inline" id="math36-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>) to be affected by the 2 health expenditures. For example, in addition to directly improving longevity and health-related quality of life, health interventions may also improve productivity in terms of the increased quantity (an increase in <inline-formula id="inline-formula14-0272989X11427958"><mml:math display="inline" id="math37-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>) and quality (an increase in <italic>w</italic>) of the time that is available for leisure and work. However, more inclusive specification of the effects of health care expenditures would not alter the analysis in this article.<sup><xref ref-type="bibr" rid="bibr2-0272989X11427958">2</xref>,<xref ref-type="bibr" rid="bibr3-0272989X11427958">3</xref>,<xref ref-type="bibr" rid="bibr6-0272989X11427958">6</xref></sup></p>
</fn>
<fn fn-type="other" id="fn9-0272989X11427958">
<label>i.</label>
<p>Note that the critical value of the cost-effectiveness ratio is <italic>u</italic>(<italic>c, l</italic>) /<italic>λ</italic> rather than 1/λ, where λ is the marginal (lifetime) utility of wealth. This is the appropriate critical value of the ratio because what is evaluated on the LHS of <xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref> is a cost-effectiveness ratio with the effectiveness being measured by QALY gains. On the other hand, if an intervention under evaluation is captured by a cost/utility ratio, then the corresponding critical value of the cost/utility ratio would be 1/λ.</p>
</fn>
<fn fn-type="other" id="fn10-0272989X11427958">
<label>j.</label>
<p>Therefore, our recommendation to opt for the exclusion option in choosing among alternative internally consistent exclusion/inclusion rules is because the exclusion option has an informational advantage, not because it represents a superior perspective, a point of view held by Richardson and Olsen.<sup><xref ref-type="bibr" rid="bibr21-0272989X11427958">21</xref></sup> Also, see Nyman<sup><xref ref-type="bibr" rid="bibr13-0272989X11427958">13</xref></sup> for a response to their view.</p>
</fn>
<fn fn-type="other" id="fn11-0272989X11427958">
<label>k.</label>
<p>See the envelope theorem result that Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> reports in his work in section 2.5 and especially the analysis on pages 44 and 45.</p>
</fn>
<fn fn-type="other" id="fn12-0272989X11427958">
<label>l.</label>
<p>In the implementation of weighting life years with health-related quality of life, it may be difficult for the respondents to perfectly separate health-related quality of life from health-unrelated quality of life associated with consumption and leisure. However, any imperfection of this kind is just an error in estimating health-related quality of life rather than an intended rule and should be treated as such. So, we agree with Nyman<sup><xref ref-type="bibr" rid="bibr9-0272989X11427958">9</xref></sup> on his reply to Gandjour<sup><xref ref-type="bibr" rid="bibr23-0272989X11427958">23</xref></sup> that inclusion of survival consumption costs and earnings cannot simply be justified on the ground that the health-related quality of life weights used to obtain the QALY measure may be contaminated with elements of health-unrelated quality of life, even though, as is clear later, we do agree with Gandjour<sup><xref ref-type="bibr" rid="bibr23-0272989X11427958">23</xref></sup> on his conclusion that survival consumption costs and earnings should be included in medical CEA.</p>
</fn>
<fn fn-type="other" id="fn13-0272989X11427958">
<label>m.</label>
<p>Note that the survival consumption costs and survival earnings are <italic>T<sub>H</sub>c</italic> and <italic>T<sub>H</sub>w</italic>(<inline-formula id="inline-formula15-0272989X11427958"><mml:math display="inline" id="math38-0272989X11427958"><mml:mrow><mml:mover><mml:mi>L</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>−<italic>l</italic>), respectively, where <italic>T<sub>H</sub></italic> is the direct longevity effect of a marginal intervention and <italic>c</italic> and <italic>l</italic> are consumption and leisure at their respective preintervention levels. This does not mean that <italic>c</italic> and <italic>l</italic> do not adjust in response to the new intervention. But, as is clear from the earlier discussion of the first feature of the criterion (<xref ref-type="disp-formula" rid="disp-formula15-0272989X11427958">equation 15</xref>), we do not need to consider the costs (or earnings) and utility (or disutility) associated with a change in <italic>c</italic> (or <italic>l</italic>) because they exactly offset each other in terms of welfare for a marginal intervention.</p>
</fn>
<fn fn-type="other" id="fn14-0272989X11427958">
<label>n.</label>
<p>In this article, we have a QALY-consistent framework in which constant consumption and leisure over time emerges as the equilibrium outcome. Using a more general framework that allows consumption and leisure to adjust over time, Meltzer<sup><xref ref-type="bibr" rid="bibr8-0272989X11427958">8</xref></sup> obtained these results about how consumption costs and earnings during the extended life that is directly caused by an intervention should be treated.</p>
</fn>
<fn fn-type="other" id="fn15-0272989X11427958">
<label>o.</label>
<p>This “nonseparable” situation is similar to a difficulty in assessing the health-related quality of life weights for QALYs. Ideally, we want to separate health-related quality of life weights from non–health-related quality of life weights, but this is sometimes practically impossible.</p>
</fn>
</fn-group>
</notes>
<ack><p>We acknowledge helpful comments on earlier versions from David Meltzer, John Nyman, and 2 anonymous reviewers. All remaining errors are our own.</p></ack>
<fn-group>
<fn fn-type="presented-at">
<p>This work was presented at the IHEA 7th World Congress on Health Economics in Beijing, China (12–15 July 2009).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X11427958">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Challenges for cost-effectiveness research</article-title>. <source>Med Decis Making</source>. <year>1986</year>;<volume>6</volume>:<fpage>194</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X11427958">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
<name><surname>Siegel</surname><given-names>JE</given-names></name>
<name><surname>Gold</surname><given-names>MR</given-names></name>
<name><surname>Kamlet</surname><given-names>MS</given-names></name>
<name><surname>Russell</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Recommendations of the Panel on Cost-Effectiveness in Health and Medicine</article-title>. <source>JAMA</source>. <year>1996</year>;<volume>276</volume>(<issue>15</issue>):<fpage>1253</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr3-0272989X11427958">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brouwer</surname><given-names>WBF</given-names></name>
<name><surname>Koopmanschap</surname><given-names>MA</given-names></name>
<name><surname>Rutten</surname><given-names>FFH</given-names></name>
</person-group>. <article-title>Productivity costs measurement through quality of life? A response to the recommendations of the US panel</article-title>. <source>Health Econ</source>. <year>1997</year>;<volume>6</volume>:<fpage>253</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X11427958">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>MF</given-names></name>
<name><surname>O’Brien</surname><given-names>B</given-names></name>
<name><surname>Stoddart</surname><given-names>GL</given-names></name>
<name><surname>Torrence</surname><given-names>GW</given-names></name>
</person-group>. <source>Methods for the Economic Evaluation of Health Care Programmes</source>. <edition>2nd ed.</edition> <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1997</year>.</citation>
</ref>
<ref id="bibr5-0272989X11427958">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garber</surname><given-names>AM</given-names></name>
<name><surname>Phelps</surname><given-names>CE</given-names></name>
</person-group>. <article-title>Economic foundations of cost-effectiveness analysis</article-title>. <source>J Health Econ</source>. <year>1997</year>;<volume>16</volume>:<fpage>1</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X11427958">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>D</given-names></name>
<name><surname>Johannesson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Inconsistencies in the ‘societal perspective’ on costs of the panel on cost-effectiveness in health and medicine</article-title>. <source>Med Decis Making</source>. <year>1999</year>;<volume>19</volume>(<issue>4</issue>):<fpage>371</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X11427958">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Rettenmaier</surname><given-names>AJ</given-names></name>
<name><surname>Saving</surname><given-names>TR</given-names></name>
</person-group>. <article-title>Indirect costs and discounting in health care decision making: the role of distortionary taxation</article-title>. <source>Contrib Econ Analysis Policy</source>. <year>2006</year>;<volume>5</volume>:<fpage>1</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X11427958">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meltzer</surname><given-names>D</given-names></name>
</person-group>. <article-title>Accounting for future costs in medical cost-effectiveness analysis</article-title>. <source>J Health Econ</source>. <year>1997</year>;<volume>16</volume>:<fpage>33</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X11427958">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nyman</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Should the consumption of survivors be included as a cost in cost-utility analysis?</article-title> <source>Health Econ</source>. <year>2004</year>;<volume>13</volume>:<fpage>417</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X11427958">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pliskin</surname><given-names>JS</given-names></name>
<name><surname>Shepard</surname><given-names>DS</given-names></name>
<name><surname>Weinstein</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Utility functions for life years and health status</article-title>. <source>Oper Res</source>. <year>1980</year>;<volume>28</volume>:<fpage>206</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X11427958">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleichrodt</surname><given-names>H</given-names></name>
<name><surname>Wakker</surname><given-names>P</given-names></name>
<name><surname>Johannesson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Characterizing QALYs by risk neutrality</article-title>. <source>J Risk Uncertain</source>. <year>1997</year>;<volume>15</volume>:<fpage>107</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X11427958">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleichrodt</surname><given-names>H</given-names></name>
<name><surname>Quiggin</surname><given-names>J</given-names></name>
</person-group>. <article-title>Life cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?</article-title> <source>J Health Econ</source>. <year>1999</year>;<volume>18</volume>:<fpage>681</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X11427958">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nyman</surname><given-names>JA</given-names></name>
</person-group>. <article-title>More on survival consumption costs in cost-utility analysis</article-title>. <source>Health Econ</source>. <year>2006</year>;<volume>15</volume>:<fpage>319</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X11427958">
<label>14.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Dolan</surname><given-names>P</given-names></name>
</person-group>. <article-title>The measurement of health-related quality of life for use in resource allocation decisions in health care</article-title>. In: <person-group person-group-type="editor">
<name><surname>Culyer</surname><given-names>AJ</given-names></name>
<name><surname>Newhouse</surname><given-names>JP</given-names></name>
</person-group> eds. <source>Handbook of Health Economics</source>, Vol. <volume>1</volume>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science B.V.</publisher-name>; <year>2000</year>. p <fpage>1724</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X11427958">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dow</surname><given-names>WH</given-names></name>
<name><surname>Philipson</surname><given-names>T</given-names></name>
<name><surname>Salai-Martin</surname><given-names>X</given-names></name>
</person-group>. <article-title>Longevity complementarities under competing risks</article-title>. <source>Am Econ Rev</source>. <year>1999</year>;<volume>89</volume>:<fpage>1358</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X11427958">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Rettenmaier</surname><given-names>AJ</given-names></name>
<name><surname>Saving</surname><given-names>TR</given-names></name>
</person-group>. <article-title>Longevity bias in costeffectiveness analysis</article-title>. <source>Health Econ</source>. <year>2008</year>;<volume>17</volume>:<fpage>523</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X11427958">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleichrodt</surname><given-names>H</given-names></name>
<name><surname>Quiggin</surname><given-names>J</given-names></name>
</person-group>. <article-title>Life cycle preferences over consumption and health: a reply to Klose</article-title>. <source>J Health Econ</source>. <year>2002</year>;<volume>21</volume>:<fpage>167</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X11427958">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viscusi</surname><given-names>WK</given-names></name>
<name><surname>Evans</surname><given-names>WN</given-names></name>
</person-group>. <article-title>Utility functions that depend on health status: estimates and economic implications</article-title>. <source>Am Econ Rev</source>. <year>1990</year>;<volume>80</volume>:<fpage>353</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr19-0272989X11427958">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sloan</surname><given-names>FA</given-names></name>
<name><surname>Viscusi</surname><given-names>WK</given-names></name>
<name><surname>Chesson</surname><given-names>HW</given-names></name>
<name><surname>Conover</surname><given-names>CJ</given-names></name>
<name><surname>Whetten-Goldstein</surname><given-names>K</given-names></name>
</person-group>. <article-title>Alternative approaches to valuing intangible health losses: the evidence of multiple sclerosis</article-title>. <source>J Health Econ</source>. <year>1998</year>;<volume>17</volume>:<fpage>475</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X11427958">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>KM</given-names></name>
<name><surname>Topel</surname><given-names>RH</given-names></name>
</person-group>. <article-title>The value of health and longevity</article-title>. <source>J Polit Econ</source>. <year>2006</year>;<volume>114</volume>:<fpage>871</fpage>–<lpage>904</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X11427958">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>JRJ</given-names></name>
<name><surname>Olsen</surname><given-names>JA</given-names></name>
</person-group>. <article-title>In defense of societal sovereignty: a comment on Nyman ‘the inclusion of survivor consumption in CUA’</article-title>. <source>Health Econ</source>. <year>2006</year>;<volume>15</volume>:<fpage>311</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X11427958">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nyman</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone</article-title>. <source>Health Econ</source>. <year>2011</year>;<volume>20</volume>:<fpage>56</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X11427958">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gandjour</surname><given-names>A</given-names></name>
</person-group>. <article-title>Consumption costs and earnings during added years of life: a reply to Nyman</article-title>. <source>Health Econ</source>. <year>2006</year>;<volume>15</volume>:<fpage>315</fpage>–<lpage>7</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>